Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, has announced its participation in the 2025 BIO CEO & Investor Conference. The event will take place on February 10-11, 2025, at the New York Marriott Marquis.
The company's management will deliver a corporate overview presentation on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room. Throughout the conference, management will be available for one-on-one meetings with registered investors and attendees. Interested parties can schedule meetings through the BIO Partnering portal, while those unable to attend can contact Yvonne Briggs at Alliance Advisors to arrange meetings with management.
Processa Pharmaceuticals (Nasdaq: PCSA), un'azienda farmaceutica in fase clinica che sviluppa terapie oncologiche di nuova generazione, ha annunciato la sua partecipazione alla 2025 BIO CEO & Investor Conference. L'evento si terrà dal 10 all'11 febbraio 2025, presso il New York Marriott Marquis.
Il management dell'azienda presenterà una panoramica aziendale martedì 11 febbraio alle 10:00 ora orientale nella Plymouth Room. Durante la conferenza, il management sarà disponibile per incontri individuali con gli investitori registrati e i partecipanti. Le parti interessate possono pianificare incontri attraverso il portale di BIO Partnering, mentre coloro che non possono partecipare possono contattare Yvonne Briggs di Alliance Advisors per organizzare incontri con il management.
Processa Pharmaceuticals (Nasdaq: PCSA), una empresa farmacéutica en etapa clínica que desarrolla terapias oncológicas de próxima generación, ha anunciado su participación en la 2025 BIO CEO & Investor Conference. El evento se llevará a cabo del 10 al 11 de febrero de 2025, en el New York Marriott Marquis.
La dirección de la empresa ofrecerá una presentación sobre la empresa el martes 11 de febrero a las 10:00 a.m. hora del este en el Plymouth Room. Durante la conferencia, la dirección estará disponible para reuniones uno a uno con inversores registrados y asistentes. Las partes interesadas pueden programar reuniones a través del portal BIO Partnering, mientras que aquellos que no puedan asistir pueden contactar a Yvonne Briggs de Alliance Advisors para organizar reuniones con la dirección.
프로세사 제약회사 (Nasdaq: PCSA)는 차세대 암 치료제를 개발하는 임상 단계의 제약 회사로, 2025 BIO CEO & Investor Conference에 참여한다고 발표했습니다. 이 행사는 2025년 2월 10일부터 11일까지 뉴욕 메리어트 마퀴스에서 열립니다.
회사의 경영진은 2월 11일 화요일 오전 10:00 동부 표준시 플리머스 룸에서 기업 개요 발표를 할 예정입니다. 컨퍼런스 기간 동안 경영진은 등록된 투자자 및 참석자와의 일대일 회의에 참석할 수 있습니다. 관심 있는 당사자는 BIO 파트너링 포털을 통해 회의를 스케줄 할 수 있으며, 참석할 수 없는 경우 Alliance Advisors의 Yvonne Briggs에게 연락하여 경영진과의 회의를 조율할 수 있습니다.
Processa Pharmaceuticals (Nasdaq: PCSA), une entreprise pharmaceutique en phase clinique développant des thérapies anticancéreuses de nouvelle génération, a annoncé sa participation à la 2025 BIO CEO & Investor Conference. L'événement se déroulera du 10 au 11 février 2025, au New York Marriott Marquis.
La direction de l'entreprise fera une présentation sur la société le mardi 11 février à 10h00, heure de l'Est, dans la Plymouth Room. Tout au long de la conférence, la direction sera disponible pour des réunions individuelles avec les investisseurs et participants enregistrés. Les parties intéressées peuvent planifier des réunions via le portail BIO Partnering, tandis que ceux qui ne peuvent pas assister peuvent contacter Yvonne Briggs d'Alliance Advisors pour organiser des réunions avec la direction.
Processa Pharmaceuticals (Nasdaq: PCSA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das Therapien der nächsten Generation für Krebserkrankungen entwickelt, hat seine Teilnahme an der 2025 BIO CEO & Investor Conference angekündigt. Die Veranstaltung findet vom 10. bis 11. Februar 2025 im New York Marriott Marquis statt.
Die Unternehmensleitung wird am Dienstag, den 11. Februar, um 10:00 Uhr Eastern Time im Plymouth Room eine Unternehmenspräsentation halten. Während der Konferenz steht das Management für persönliche Treffen mit registrierten Investoren und Teilnehmern zur Verfügung. Interessierte Parteien können über das BIO Partnering-Portal Meetings planen, während diejenigen, die nicht teilnehmen können, Yvonne Briggs von Alliance Advisors kontaktieren können, um Meetings mit dem Management zu arrangieren.
- None.
- None.
HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO & Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis.
Management will present a corporate overview on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. Those interested in scheduling a meeting with Processa management are encouraged to do so through the BIO Partnering portal. For those not attending the conference who are interested in meeting with Processa management, please contact Yvonne Briggs at ybriggs@allianceadvisors.com.
About Processa Pharmaceuticals, Inc.
Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.
For more information, visit our website at www.processapharma.com.
Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com
Investor Relations Contact:
Yvonne Briggs
Alliance Advisors IR
(310) 691-7100
ybriggs@allianceadvisors.com
# # #
FAQ
When is Processa Pharmaceuticals (PCSA) presenting at the 2025 BIO CEO Conference?
How can investors schedule meetings with PCSA management at the 2025 BIO CEO Conference?
Where is the 2025 BIO CEO & Investor Conference being held for PCSA's presentation?
What is the focus of Processa Pharmaceuticals' (PCSA) research and development?
